Document:

ex10-1.htm

EXHIBIT 10.1

 

Via email 

June 13, 2017

 

Mr. Samuel Dortch

2800 Gap Road

Batesville, Arkansas 72501

 

 

Re:     Retirement from FutureFuel 

 

 

 

Sam, as further discussed, below confirms our understanding on your retirement.

 

	 	
			●

				
			You will retire at the end of 2017.

			

 

	 	
			●

				
			Beginning January 1, 2018, you will be a consultant on an as needed basis at a rate of $100 per hour. For 2018, you will receive minimum aggregate consultancy fees of $100,000.

			

 

	 	
			●

				
			After 2018, consulting remains on an as needed basis at a rate of $100 per hour.

			

 

	 	
			●

				
			No consultancy fee will be paid for your travel time, however, FutureFuel will reimburse your travel expenses for related work. Reimbursement for such travel expenses will apply even if you relocate your primary residence from Batesville as long as your relocation is within the contiguous United States.

			

 

	 	
			●

				
			If you decide to move from your current primary residence in Batesville before the end of 2017 and have listed it on the market for sale for at least six consecutive months prior to July 1, 2018 without success of sale, FutureFuel will purchase your current primary residence in Batesville for fair market value. If fair market value cannot be agreed between you and FutureFuel, fair market value will be determined by the average of the prices of two appraisals (one to be conducted on behalf of you and another on behalf of FutureFuel).

			

 

 

/s/ Paul A. Novelly

Paul A. NovellyExhibit

    
EXHIBIT 10.2

                    
	
		
	Sarah Noonberg
[Address]
	     UPDATED - March 29, 2017

Dear Sarah:

I am pleased to confirm this offer for you to join Prothena Biosciences Inc (“Prothena” or the “Company”).  We are confident in your knowledge, expertise and judgment, and believe your performance will meet our team’s high-quality objectives and standards.

You will be appointed as Chief Medical Officer by the Board of Directors of Prothena Corporation plc at its next meeting, scheduled to be held on May 16.  In this position, you will report to Gene Kinney (CEO and President), although your duties, title and reporting relationship may change, based on the Company’s needs and priorities.  This is a full-time, exempt position.

Your starting salary will be $465,000.00/year, paid twice per month.  Your pay is subject to applicable taxes and withholdings.

We agree to pay you a retention bonus of $100,000.00 (gross) which will be fully earned in the event that you remain employed with Prothena for one year.  We agree to advance you the entire bonus in your first paycheck, less applicable taxes and withholdings.  This bonus will be earned on a pro-rata basis for each week worked during your initial one-year period of employment at Prothena.  The unearned portion of this bonus will be repayable by you to Prothena on a pro-rata basis if you cease employment at Prothena prior to the one-year anniversary of your Start Date of employment, unless your employment ends for a reason that would make you eligible for severance benefits in accordance with the Prothena Biosciences Inc Amended and Restated Severance Plan.

Prothena embraces a pay-for-performance philosophy.  All employees are currently eligible for an annual cash bonus under the terms of the Company's cash incentive plan (the Prothena Corporation plc Amended and Restated Incentive Compensation Plan).  The amount of these annual cash bonuses are determined by the Company on the basis of a number of factors, including industry competitiveness, Prothena’s business strategy, and the degree to which Company, function and/or individual goals are met.  Your targeted cash bonus will be 40% of your actual plan year salaried earnings.  A condition to earning a cash incentive award is that you remain employed through the pay date of any otherwise earned award, which will be paid no later than March 15 in the year following the conclusion of the plan year.  The cash bonus plan is operated at the sole discretion of Prothena, is subject to review on a regular basis and may change from time to time.

In connection with your commencement of employment, you will also be eligible to receive an option to acquire 100,000 shares of Prothena Corporation plc.  This stock option award is at the discretion of the Compensation Committee of the Board of Directors of Prothena Corporation plc (the “Committee”) and is subject to the terms and conditions of the Prothena Corporation plc Amended and Restated 2012 Long Term Incentive Plan and the terms and conditions of the award agreement for such a stock option.  The grant date of this stock option will be May 16, 2017 or on such other date as determined by the Committee in its sole discretion.  The option exercise price will be equal to the closing price of Prothena Corporation plc’s ordinary shares on the NASDAQ Global Select Market on that date.  Subject to your continued employment, the stock option will vest 25% on the first anniversary of the grant date, and monthly at a rate of 1/48th of the award thereafter, such that the option will fully vest after a four-year period of continuous employment.

On the first day of the month following your Start Date, you will be eligible to participate in Prothena’s comprehensive health and welfare benefits program.  On your Start Date, you will also be eligible to participate in our retirement benefits plan, as well as the Prothena Biosciences Inc Amended and Restated Severance Plan.  Details about these and other applicable plans will be provided separately.

Further information regarding onboarding requirements and/or documents needed before or after your employment start date (e.g., Employee Proprietary Information and Invention Assignment Agreement, Code of Conduct, Form I-9 completion process, direct deposit information, Form W-4 allowance elections) will be provided separately.

Prothena’s offer of employment is contingent upon our receiving satisfactory results from your references, background check and drug screening, as well as any other pre-employment testing that may be required due to the specific nature of our industry and/or your position.  Your employment is “at will.”  This means that you and Prothena each have the right to terminate the employment relationship at any time, with or without cause.  Nothing in this letter should be taken as a guarantee of continued employment or a specific term of employment.  Further, all benefits and compensation provided by the Company are contingent upon your continued employment.

To ensure rapid and economical resolution of any disputes regarding your employment under this offer letter, the parties hereby agree that any and all claims, disputes or controversies of any nature whatsoever arising out of, or relating to, this offer letter, or its interpretation, enforcement, breach, performance or execution, your employment with the Company/ or the termination of such employment, shall be resolved, to the fullest extent permitted by law, by final, binding and confidential arbitration in San Francisco, CA conducted before a single arbitrator by JAMS, Inc. (“JAMS”) or its successor, under the then applicable JAMS arbitration rules.  The parties each acknowledge that by agreeing to this arbitration procedure, they waive the right to resolve any such dispute, claim or demand through a trial by jury or judge or by administrative proceeding.  You may be represented by legal counsel at any arbitration proceeding.  The arbitrator shall: (i) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be available under applicable law in a court proceeding; and

(ii) issue a written statement signed by the arbitrator regarding the disposition of each claim and the relief, 
if any, awarded as to each claim, the reasons for the award, and the arbitrator’s essential findings and conclusions on which the award is based.  The arbitrator, and not a court, shall also be authorized to determine whether the provisions of this paragraph apply to a dispute, controversy, or claim sought to be resolved in accordance with these arbitration procedures.  The parties will share the costs of arbitration equally except that the Company will bear the cost of the arbitrator’s fee, any other type of expense or cost that the employee would not be required to bear if the employee were to bring the dispute or claim in court.  Both parties will be responsible for their own attorney’s fees, and the arbitrator may not award attorney’s fees unless a statute or contract at issue specifically authorizes such an award.  This arbitration provision does not apply to claims concerning worker’s compensation or unemployment insurance claims.  Nothing in this Agreement is intended to prevent either you or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any arbitration.

To accept our offer, please sign this letter and return it to Kevin Hickey by April 3, 2017.  By signing this letter, you acknowledge that it sets out our entire agreement between you and the Company and supersedes all prior oral and written agreements, understandings, commitments and practices.  No amendments to this agreement may be made except in writing signed by a duly authorized representative of Prothena.

We look forward to having you join Prothena as a full-time employee.  If you have any questions, or would like additional information to help you reach a decision, please feel free to contact Kevin at (650) 837-8545.

Sincerely,

/s/ Gene Kinney

Gene Kinney
President and CEO
Prothena Biosciences Inc

ACCEPTANCE:

/s/ Sarah Noonberg                  2 April 2017      
Sarah Noonberg            DateExhibit

    

                        
	
		
	Wagner M. Zago, Ph.D.
[Address]

	June 9, 2017

Dear Wagner:

I am pleased to confirm your promotion and appointment as Chief Scientific Officer by the Board of Directors of Prothena Corporation plc.  In this position, you will continue to report to me, although your duties, title and reporting relationship may change, based on the Company’s needs and priorities.  

Effective the beginning of the current payroll period (i.e., June 1), your new salary will be $345,000.00/year, paid twice per month.  Your pay is subject to applicable taxes and withholdings.

As you know, Prothena embraces a pay-for-performance philosophy.  You will continue to eligible for an annual cash bonus under the terms of the Company’s cash incentive plan (the Prothena Corporation plc Amended and Restated Incentive Compensation Plan).  The amount of these annual cash bonuses are determined by the Company on the basis of a number of factors, including industry competitiveness, Prothena’s business strategy, and the degree to which Company, function and/or individual goals are met.  Effective June 1, 2017, your targeted cash bonus will be increased from 30% to 40% of your actual plan year salaried earnings (pro-rated for the period after that date).  A condition to earning a cash incentive award is that you remain employed through the pay date of any otherwise earned award, which will be paid no later than March 15 in the year following the conclusion of the plan year.  The cash bonus plan is operated at the sole discretion of Prothena, is subject to review on a regular basis and may change from time to time.

In connection with your appointment as Chief Scientific Officer, you are being granted, on the date of this letter, an option to acquire 20,000 shares of Prothena Corporation plc.  This stock option award is subject to the terms and conditions of the Prothena Corporation plc Amended and Restated 2012 Long Term Incentive Plan and the terms and conditions of the award agreement for such a stock option.  The option exercise price will be equal to the closing price of Prothena Corporation plc’s ordinary shares on the NASDAQ Global Select Market on today’s date.  Subject to your continued employment, the stock option will vest 25% on the first anniversary of the grant date, and monthly at a rate of 1/48th of the award thereafter, such that the option will fully vest after a four-year period of continuous employment. 

You will continue to be eligible to participate in Prothena Biosciences Inc’s comprehensive health and welfare benefits program, retirement benefits plan, and the Prothena Biosciences Inc Amended and Restated Severance Plan, but your participation will now be as a Tier 1 employee.  

Your employment with Prothena Biosciences Inc continues to be “at will.”  This means that you and the Company each have the right to terminate the employment relationship at any time, with or without cause.  Nothing in this letter should be taken as a guarantee of continued employment or a specific term of employment.  Further, all benefits and compensation provided by the Company are contingent upon your continued employment.

    

To ensure rapid and economical resolution of any disputes regarding your employment, the parties hereby agree that any and all claims, disputes or controversies of any nature whatsoever arising out of, or relating to, this offer letter, or its interpretation, enforcement, breach, performance or execution, your employment with the Company and/or the termination of such employment, shall be resolved, to the fullest extent permitted by law, by final, binding and confidential arbitration in San Francisco, CA conducted before a single arbitrator by JAMS, Inc. (“JAMS”) or its successor, under the then applicable JAMS arbitration rules.  The parties each acknowledge that by agreeing to this arbitration procedure, they waive the right to resolve any such dispute, claim or demand through a trial by jury or judge or by administrative proceeding.  You may be represented by legal counsel at any arbitration proceeding.  The arbitrator shall: (i) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be available under applicable law in a court proceeding; and (ii) issue a written statement signed by the arbitrator regarding the disposition of each claim and the relief, if any, awarded as to each claim, the reasons for the award, and the arbitrator’s essential findings and conclusions on which the award is based.  The arbitrator, and not a court, shall also be authorized to determine whether the provisions of this paragraph apply to a dispute, controversy, or claim sought to be resolved in accordance with these arbitration procedures.  The parties will share the costs of arbitration equally except that the Company will bear the cost of the arbitrator’s fee, any other type of expense or cost that the employee would not be required to bear if the employee were to bring the dispute or claim in court.  Both parties will be responsible for their own attorney’s fees, and the arbitrator may not award attorney’s fees unless a statute or contract at issue specifically authorizes such an award.  This arbitration provision does not apply to claims concerning worker’s compensation or unemployment insurance claims.  Nothing in this Agreement is intended to prevent either you or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any arbitration.

To confirm the above, please sign this letter and return it to Kevin Hickey.  By signing this letter, you acknowledge that it sets out our entire agreement between you and the Company and supersedes all prior oral and written agreements, understandings, commitments and practices.  No amendments to this agreement may be made except in writing signed by a duly authorized representative of Prothena.

Sincerely,

/s/ Gene Kinney

Gene Kinney
President and CEO
Prothena Biosciences Inc

ACCEPTANCE:

            /s/ Wagner M. Zago                            6-09-17                                     
Wagner M. Zago                    Date

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}]]